Molecular Partners Announces Publication in Cancer Immunology Research of Preclinical Data Supporting MP0533's Proposed Mechanism of Action

Preclinical data of tetra-specific T cell engager MP0533 demonstrate preferential T cell mediated killing of AML cells, while sparing healthy cellsResults highlight MP0533-mediated T-cell activation...

Related Keywords

Zurich ,Züsz ,Switzerland ,United States ,Bern ,Massachusetts ,American ,Seth Lewis ,Laura Jeanbart ,University Of Bern ,Cancer Immunology Research ,Linkedin ,American Association For Cancer Research ,Head Of Portfolio Management Communications ,Exchange Commission ,American Society Of Hematology ,Nasdaq ,American Association ,Cancer Research The ,American Society ,Annual Meeting ,Selectivet Cell ,Mediated Killing ,Immunol Res ,Designed Ankyrin Repeat Protein ,Portfolio Management ,Private Securities Litigation Reform Act ,Molecular Partner ,Risk Factors ,Molecular Partner Annual Report ,Molecular Partners ,Markets ,